Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,014 public trials 2,030 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Completed

506U78 In Relapsed Or Refractory Acute Lymphoblastic Leukemia (T-ALL)

NCT00684619

Conditions
Hematologic Diseases, Hemic and Lymphatic Diseases, Immune System Diseases, +10 more
Locations
  • Robert Bosch Krankenhaus Stuttgart, Baden-Wurttemberg, Germany
  • Klinikum der Universität Regensburg Regensburg, Bavaria, Germany
  • University Hospital of Frankfurt, Medical Dept. II Frankfurt am Main, Hesse, Germany
  • Medizinische Hochschule Hannover Hanover, Lower Saxony, Germany
View Trial Details
Completed

S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma

NCT00822120

Conditions
Blood-Borne Infections, Communicable Diseases, Genital Diseases, +20 more
Locations
  • Arizona Cancer Center at University Medical Center North Tucson, Arizona, United States
  • Arizona Cancer Center at University of Arizona Health Sciences Center Tucson, Arizona, United States
  • Arkansas Cancer Research Center at University of Arkansas for Medical Sciences Little Rock, Arkansas, United States
  • Highlands Oncology Group - Springdale Rogers, Arkansas, United States
View all 423 locations
View Trial Details
Completed

Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)

NCT03527147

Conditions
DLBCL, Diffuse Large B Cell Lymphoma, Hemic and Lymphatic Diseases, +12 more
Locations
  • Research Site Los Angeles, California, United States
  • Research Site Sarasota, Florida, United States
  • Research Site Atlanta, Georgia, United States
  • Research Site New Orleans, Louisiana, United States
View Trial Details
Completed

Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients

NCT03630159

Conditions
Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • Emory University School of Medicine SC CTL019 Atlanta, Georgia, United States
  • University of Chicago Medical Center Hematology and Oncology Chicago, Illinois, United States
  • University of Kansas Hospital and Medical Center U of Kansas Cancer Center Kansas City, Kansas, United States
  • Novartis Investigative Site Vienna, Austria
View Trial Details

Related conditions